This information was received as a part of an extensive mesh litigation submission to medtronic.
The fda was notified of this large complaint receipt.
Due to the volume of complaint information received by medtronic, this resulted in a report beyond the 30 day target.
H6:patient code-c64343(evisceration; dehydration; leukocytosis).
If information is provided in the future, a supplemental report will be issued.
|
The patient¿s attorney alleged a deficiency against the device.
The product was used for therapeutic treatment of a recurrent ventral incisional hernia.
It was reported that after implant, the patient experienced recurrence, wound dehiscence with evisceration, grossly distended abdomen, drainage from skin incision, bowel nearly protruding through skin incision, light fibrinous inflammatory adhesions, extensive gaseous distended ileus, sepsis, respiratory failure, purulent material in subcutaneous space, fibrinous adhesions, abdominal bloating, nausea, vomiting, non-healing wound on abdomen, bowel obstruction, dehydration, acute renal failure, leukocytosis, and multiple hospitalizations.
Post-operative patient treatment included revision surgeries, lysis of adhesions, exploratory laparotomy, and mesh removal.
|